4 курс / Дерматовенерология / Папуло_пустулезная_форма_розацеа_у_женщин_Хворик_Д
.pdf148.Determination of tear and serum inflammatory cytokines in patients with rosacea using multiplex bead technology / P. Topcu-Yilmaz [et al.] // Ocul. Immunol. Inflamm. – 2013. – Vol. 21, № 5. –Р. 351–359.
149.Effect of lactoferrin on the ferroxidase activity of ceruloplasmin
/A. V. Sokolov [et al.] // Biochemistry (Mosc). – 2005. – Vol. 70, № 9. – Р. 1015–1019.
150.Elewski, B. E. A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results
of a randomized trial / B. E. Elewski, A. B. Jr. Fleischer,
D.M. Pariser // Cutis. – 2003. – Vol. 139, № 11. – Р. 1444–1450.
151.Erythema of Rosacea Impairs Health-Related Quality of Life: Results of a Meta-analysis / A. Bewley [et al.] // Dermatol. Ther. (Heidelb). – 2016. – Vol. 6, № 2. – Р. 237–247.
152.Evidence for a critical role of ceruloplasmin oxidase activity in iron metabolism of Wilson disease gene knockout mice / U. Merle [et al.] // J. Gastroenterol. Hepatol. – 2010. – Vol. 25, № 6. – Р. 1144–1150.
153.Expression of vascular endothelial growth factor and its receptors in rosacea / J. R. Smith [et al.] // Br. J. Ophthalmol. – 2007. – Vol. 91, № 2. – P. 226–229.
154.Fernandez-Obregon, A. The role of Chlamydia pneumoniae in the
etiology of acne rosacea: response to the use of oral azithromycin / A. Fernandez-Obregon, D. L. Patton // Cutis. – 2007. – Vol. 79, № 2. – Р. 163–167.
155.Ferrara, N. The biology of VEGF and its receptors / N. Ferrara, H. P. Gerber, J. LeCouter // Nat. Med. – 2003. – Vol. 9, № 6. – Р. 669–676.
156.Findley, K. Topographic diversity of fungal and bacterial communities in human skin / K. Findley [et al.] // Nature. – 2013. – Vol. 498 (7454). – Р. 367–370.
157.Forton, F. M. Papulopustular rosacea, skin immunity and
Demodex: pityriasis folliculorum as a missing link / F. M. Forton
//J. Eur. Acad. Dermatol. Venereol. – 2012. – Vol. 26, № 1. – Р. 19–28.
158.Fowler, J. F. Jr. Combined effect of anti-inflammatory dose doxycycline (40-mg doxycycline, usp monohydrate controlled-release
capsules) and metronidazole topical gel 1% |
in the |
treatment of |
rosacea |
/ J. F. Jr. Fowler // J. Drugs Dermatol. – |
2007. |
– Vol. 6, |
№ 6. – |
Р. 641–645. |
|
|
|
159.Gabay, C. IL-1 pathways in inflammation and human diseases
/C. Gabay, C. Lamacchia, G. Palmer // Nat. Rev. Rheumatol. – 2010. –
Vol. 6, № 4. – Р. 232–241.
~111 ~
160. Goldberg, D. J. Combination blue (415 nm) and red (633 nm) LED phototherapy in the treatment of mild to severe acne vulgaris / D. J. Goldberg, B. A. Russell // J. Cosmet. Laser Ther. – 2006. – Vol. 8,
№2. – Р. 71–75.
161.Grice, E. A. The skin microbiome: potential for novel diagnostic and therapeutic approaches to cutaneous disease / E. A. Grice // Semin. Cutan. Med. Surg. – 2014. – Vol. 33, № 2. – Р. 98–103.
162.GSTM1 and GSTT1 null genotypes as possible heritable factors of rosacea / A. C. Yazici [et al.] // Photodermatol. Photoimmunol. Photomed.
– 2006. – Vol. 22, № 4. – Р. 208–210.
163.Guffey, J. S. In vitro bactericidal effects of 405-nm and 470-nm blue light / J. S. Guffey, J. Wilborn // Photomed. Laser Surg. – 2009. –
Vol. 24, № 6. – Р. 684–688.
164. Gupta, A. K. Rosacea and its management: an overview / A. K. Gupta, M. M. Chaudhry // J. Eur. Acad. Dermatol. Venereol. – 2005.
–Vol. 19. – P. 273–285.
165.Jackson, J. M. Efficacy of extended-release 45 mg oral minocycline and extended-release 45 mg oral minocycline plus 15% azelaic acid in the treatment of acne rosacea / J. M. Jackson, H. Kircik, D. J. Lorenz // J. Drugs. Dermatol. – 2013. – Vol. 12, № 3. – P. 292–298.
166.Jarmolik, E. Rola czynnika wzrostu srodblonka naczyniowego
I |
cytokine |
prozapalnych |
w |
rozwoju |
tradziku |
rozowatego |
/E. Jarmolik, D. Chworyk // 11-я Академия дерматологии и аллергологии : тез. междунар. науч.-практ. конф., Устка (Польша), 5-8 февр. 2015 г. –
Устка, 2015. – С. 98.
167.Jones, D. A. Rosacea, reactive oxygen species, and azelaic Acid
/D. A. Jones // J. Clin. Aesthet. Dermatol. – 2009. – Vol. 2, № 1. – P. 26–30.
168. Jones, D. Reactive oxygen species and rosacea / D. Jones
//Cutis. – 2004. – Vol. 74, № 3. – P. 17–20.
169.Health-related quality of life in patients with cutaneous rosacea: a systematic review / M. M. van der Linden [et al.] // Acta Derm. Venereol. – 2015. – Vol. 95, № 4. – Р. 395–400.
170.Holmes, A. D. Potential role of microorganisms in the pathogenesis of rosacea / A. D. Holmes // J. Am. Acad. Dermatol. – 2013. –
Vol. 69, № 6. – Р. 1025–1032.
171.Horiuchi, Y. FK506 (tacrolimus) inhibition of intracellular production and enhancement of interleukin 1alpha through glucocorticoid application to chemically treated human keratinocytes / Y. Horiuchi,
~112 ~
S. Bae, I. Katayama // Skin Pharmacol. Physiol. – 2005. – Vol. 18, № 5. – Р. 241–246.
172. Human Microbiome: When a Friend Becomes an Enemy
/M. Muszer [et al.] // Arch. Immunol. Ther. Exp. (Warsz.). – 2015. –
Vol. 63, № 4. – Р. 287–298.
173.Kaszuba-Bartkowiak, K. The assessment of bacterial flora and antibiotic-sensitivity of bacteria isolated from conjunctival sac, skin of the eyelids and inflammatory lesions in patients with acne vulgaris and rosacea
/K. Kaszuba-Bartkowiak, R. Goś // Przegl. Lek. – 2007. – Vol. 64, № 12. –
P. 991–996.
174.Khvorik, D. Lipid peroxidation and antioxidant protection in
patients with papulo-pustular rosacea / D. Khvoryk, A. Yarmolik
//Progress in health sciences. – 2015. – Vol. 5, № 2. – Р. 54–60.
175.Khvorik, D. Treatment of papulo-pustular rosacea using blue and red light / D. Khvorik, A. Yarmolik // 12-я Академия дерматологии и аллергологии : тез. междунар. науч.-практ. конф., Устка (Польша), 5–7 февр. 2016 г. – Устка, 2016. – С. 70–71.
176.Kökçam, I. M. Antioxidants and lipid peroxidation status in the blood of patients with psoriasis / I. Kökçam, M. Naziroğlu // Clin. Chim. Acta. – 1999. – Vol. 289, № 1/2. – P. 23–31.
177.Lee, S. Y. Blue and red light combination LED phototherapy for
acne vulgaris in patients with skin phototype IV / S. Y. Lee, C. E. You, M. Y. Park // Lasers Surg. Med. – 2007. – Vol. 39, № 2. –
P. 180–188. |
|
|
|
178. Lipid peroxidation and antioxidant |
status |
in lichen |
planus |
/ E. Sezer [et al.] // Clin. Exp. Dermatol. – |
2007. – |
Vol. 32, |
№ 4. – |
Р. 430–434. |
|
|
|
179.Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations
/J. Frostegаrd [et al.] // Arthritis Rheum. – 2005. – Vol. 52 (1). – P. 192–200.
180.Low-power light and isolated rat hearts after ischemia of myocardium / V. Monich [et al.] // J. Photochem. Photobiol. – 2011. – Vol. 105, № 1. – Р. 21–24.
181.Lymphangiogenesis and angiogenesis in non-phymatous rosacea
/A. H. Gomaa [et al.] // J. Cutan. Pathol. – 2007. – Vol. 34, № 10. – Р. 748– 753.
182.Major pathophysiological correlations of rosacea: a complete clinical appraisal / R. C. Vemuri [et al.] // Int. J. Med. Sci. – 2015. – Vol. 12, № 5. – Р. 387–396.
~113 ~
183.Managing rosacea: a review of the use of metronidazole alone and in combination with oral antibiotics / J. F. Conde [et al.] // J. Drugs Dermatol.
–2007. – Vol. 6, № 5. – Р. 495–498.
184.McKeage, K. Doxycycline 40 mg capsules (30 mg immediate-
release/10 mg delayed-release beads): anti-inflammatory dose |
in rosacea |
/ K. McKeage, E. D. Deeks // Am. J. Clin. Dermatol. – 2010. |
– Vol. 11, |
№3. – Р. 217–222.
185.Molecular and Morphological Characterization of Inflammatory Infiltrate in Rosacea Reveals Activation of Th1/Th17 Pathways / T. Buhl [et al.] // J. Invest. Dermatol. – 2015. – Vol. 135, № 9. – Р. 2198–2208.
186.Murillo, N. Skin microbiota: overview and role in the skin diseases acne vulgaris and rosacea / N. Murillo, D. Raoult // Future Microbiol. – 2013. – Vol. 8, № 2. – Р. 209–222.
187.Murphy, J. E. Interleukin-1 and cutaneous inflammation: a crucial link between innate and acquired immunity / J. E. Murphy, C. Robert, T. S. Kupper // J. Invest. Dermatol. – 2000. – Vol. 114, № 3. – Р. 602–608.
188.MyD88 mediates neutrophil recruitment initiated by IL-1R but
not TLR2 activation in immunity against Staphylococcus aureus
/L. S. Miller [et al.] // Immunity. – 2006. – Vol. 24, № 1. – Р. 79–91.
189.Mzhel'skaya, T. I. Biological functions of ceruloplasmin and their deficiency caused by mutation in genes regulating copper and iron metabolism / T. I. Mzhel'skaya // Bull. Exp. Biol. Med. – 2000. – Vol. 130, № 8. – Р. 719–727.
190.New antibiotic therapies for acne and rosacea / R. M. Mays [et al.] // Dermatol. Ther. – 2012. – Vol. 25, № 1. – Р. 23–37.
191.Oxidant-antioxidant enzymes and lipid peroxidation in generalized vitiligo / R. Koca [et al.] // Clin. Exp. Dermatol. – 2004. – Vol. 29 (4). – P. 406–409.
192.Oxidative stress and ferritin expression in the skin of patients with rosacea / V. S. Tisma [et al.] // J. Am. Acad. Dermatol. – 2009. – Vol. 60, № 2. – Р. 270–276.
193.Oxidative stress and its role in skin disease / K. J. Trouba [et al.] // Antioxid. Redox. Signal. – 2002. – Vol. 4, № 4. – P. 665–673.
194.Papageorgiou, P. Phototherapy with blue (415 nm) and red (660
nm) light in the treatment A. Katsambas, A. Chu // Br. J. Р. 973–978.
of acne vulgaris / P. Papageorgiou, Dermatol. – 2000. – Vol. 142, № 5. –
~ 114 ~
195.Park, H. Use of Oral Isotretinoin in the Management of Rosacea
/H. Park, J. Q. Del Rosso // J. Clin. Aesthet. Dermatol. – 2011. – Vol. 4, № 9. – Р. 54–61.
196.Picardo M. Skin microbiome and skin disease: the example of rosacea / M. Picardo, M. Ottaviani // J. Clin. Gastroenterol. – 2014. –
Vol. 48, № 1. – Р. 85–86.
197.Plasma reactive oxygen species activity and antioxidant potential levels in rosacea patients: correlation with seropositivity to Helicobacter
pylori / K. Baz [et al.] |
// |
Int. J. Dermatol. – 2004. – Vol. 43, № 7. – |
P. 494–497. |
|
|
198. Powell, F. |
C. |
Rosacea and the pilosebaceous follicle |
/F. C. Powell // Cutis. – 2004. – Vol. 74, № 3. – P. 9–12, 32–34.
199.Prevalence of skin diseases in a cohort of 48,665 employees in Germany / I. Schaefer [et al.] // Dermatology – 2008. – Vol. 217, № 2. – P. 169 – 172.
200.Proand anti-inflammatory forms of interleukin-1 in the tear fluid
and conjunctiva of patients with dry-eye disease / A. Solomon [et al.]
//Invest. Ophthalmol. Vis. Sci. – 2001. – Vol. 42, № 10. – Р. 2283–2292.
201.Reactive oxygen intermediates increase vascular endothelial
growth factor expression in vitro and in vivo / M. Kuroki [et al.]
//J. Clin. Invest. – 1996. – Vol. 98, № 7. – Р. 1667–1675.
202.Reactive oxygen species in tumor necrosis factoralphaactivated primary human keratinocytes: implications for psoriasis and inflammatory skin disease / С. N. Young [et al.] // J. Invest. Dermatol. – 2008. –
Vol. 128, № 11. – Р. 2606–2614.
203. Rebora, A. Helicobacter pylori in patients with rosacea / A. Rebora, F. Drago, A. Picciotto // Am. J. Gastroenterol. – 1994. – Vol. 89, № 9. – Р. 1603-1604.
204.Redox thiol status plays a central role in the mobilization and metabolism of nitric oxide in human red blood cells / J. P. L. Almeida [et al.]
//Cell. Biol. Int. – 2009. – Vol. 33, № 3. – Р. 268–275.
205.Reflectance confocal microscopy for monitoring the density of
Demodex mites in patients with rosacea before and after treatment
/E. C. Sattler [et al.] // Br. J. Dermatol. – 2015. – Vol. 173, № 1. – Р. 69–75.
206.Regulation of VEGF expression in cultured keratrinocytes:
Implications for normal and impaired wound healing / S. Frank [et al.]
//J. Biol. Chem. – 1995. – Vol. 270, № 21. – Р. 12607–12613.
~115 ~
207.Report of the Consensus Conference on Acne Classification, Washington, D.C., March 24-25 1990 / P. E. Pochi [et al.] // J. Am. Acad. Dermatol. – 1991. – Vol. 24, № 3. – P. 495–500.
208.Risk factors associated with rosacea / K. Abram [et al.] // J. Eur. Acad. Dermatol. Venereol. – 2010. – Vol. 24, № 5. – P. 565–571.
209.Robledo, M. A. Hypothesis of demodicidosis rosacea flushing etiopathogenesis / M. A. Robledo, M. Orduz // Med. Hypotheses. – 2015. –
Vol. 84, № 4. – P. 408–412.
210.Role of oxidative stress and the antioxidant network in cutaneous carcinogenesis / C. S. Sander [et al.] // Int. J. Dermatol. – 2004. – Vol. 43,
№5. – Р. 326–335.
211.Rosacea – global diversity and optimized outcome: proposed
international consensus from the Rosacea International Expert Group
/B. E. Elewski [et al.] // J. Eur. Acad. Dermatol. Venereol. – 2011. – Vol. 25, № 2. – Р. 188–200.
212.Rosacea: The cytokine and chemokine network / P. A. Gerber [et al.] // J. Investig. Dermatol. Symp. Proc. – 2011. – Vol. 15, № 1. – Р. 40–47.
213.Rosacea treatment with intermediate-dose isotretinoin: follow-up with erythema and sebum measurements / M. Uslu [et al.] // Acta Derm. Venereol. – 2012. – Vol. 92, № 1. – Р. 73–77.
214.Sadick, N. A study to determine the effect of combination blue (415 nm) and near-infrared (830 nm) light-emitting diode (LED) therapy for moderate acne vulgaris / N. Sadick // J. Cosmet. Laser Ther. – 2009. –
Vol. 11, № 2. – Р. 125–128.
215.Schauber, J. Expanding the roles of antimicrobial peptides in skin: alarming and arming keratinocytes / J. Schauber, R. L. Gallo // J. Invest. Dermatol. – 2007. – Vol. 127, № 3. – Р. 510–512.
216.Sedlak, J. Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent / J. Sedlak, R. H. Lindsay // Anal. Biochem. – 1968. – Vol. 25, № 1. – Р. 192–205.
217.Sensitive skin in the American population: prevalence, clinical data, and role of the dermatologist / L. Misery [et al.] // Int. J. Dermatol. – 2011. – Vol. 50, № 8. – Р. 961–967.
218.Small intestinal bacterial overgrowth in rosacea: clinical effectiveness of its eradication / A. Parodi [et al.] // Clin. Gastroenterol. Hepatol. – 2008. – Vol. 6, № 7. – Р. 759–764.
219.Standard classification of rosacea: Report of the National Rosacea Sosiety Expert Committee on the Classsification and Standing of Rosacea
/J. Wilkin [et al.] // J. Am. Acad. Dermatol. – 2002. – Vol. 15. – P. 584–587.
~116 ~
220.Standard grading system for rosacea: Report of the National Rosacea Sosiety Expert Committee on the classsification and standing of rosacea / J. Wilkin [et al.] // J. Am. Acad. Dermatol. – 2004. – Vol. 50. – P. 907–912.
221.Staphylococcus epidermidis: a possible role in the pustules of rosacea / M. Whitfeld [et al.] // J. Am. Acad. Dermatol. – 2011. – Vol. 64,
№ 1. – Р. 49–52.
222.Steinhoff, M. New insights into rosacea pathophysiology: a review of recent findings / M. Steinhoff, J. Schauber, J. J. Leyden // J. Am. Acad. Dermatol. – 2013. – Vol. 69, № 6. – Р. 15–26.
223.Symptom severity and psychological sequelae in rosacea: results of a survey / D. Böhm [et al.] // Psychol. Health Med. – 2014. – Vol. 19, № 5.
– Р. 586–591.
224.Systemic isotretinoin in the treatment of rosacea – doxycycline –
and placebo-controlled, randomized clinical study / H. Gollnick [et al.]
//J. Dtsch. Dermatol. Ges. – 2010. – Vol. 8, № 7. – Р. 505–515.
225.Szlachcic, A. The link between Helicobacter pylori infection and rosacea / A. Szlachcic // J. Eur. Acad. Dermatol. Venereol. – 2002. – Vol. 16, № 4. – Р. 328–333.
226.Tan, J. Rosacea: current state of epidemiology / J. Tan, M. Berg
//J. Am. Acad. Dermatol. – 2013. – Vol. 69, № 6. – Р. 27–35.
227.Taylor, S. L. Sensitive fluorometric method for tissue tocopherol analysis / S. L. Taylor, M. P. Lamden, A. L. Tappel // Lipids. – 1976. –
Vol. 11, № 7. – P. 530–538.
228.The effect of azithromycin on reactive oxygen species in rosacea / O. Bakar [et al.] // Clin. Exp. Dermatol. – 2007. – Vol. 32, № 2. – P. 197–200.
229.The fatty acid profile of the skin surface lipid layer in papulopustular rosacea / S. Ní Raghallaigh [et al.] // Br. J. Dermatol. – 2012.
– Vol. 166, № 2. – Р. 279–287.
230.The impact of rosacea on quality of life: effects of demographic and clinical characteristics and various treatment modalities / B. Aksoy [et al.] // Br. J. Dermatol. – 2010. – Vol. 163, № 4. – Р. 719–725.
231.The mechanism of interaction of ceruloplasmin with superoxide radicals / A. G. Sergeev [et al.] // Int. J. Biochem. – 2000. – Vol. 25, № 11. – Р. 1549–1554.
232.Theobald, K. Anti-inflammatory dose doxycycline (40 mg controlled-release) confers maximum anti-inflammatory efficacy in rosacea
~117 ~
/ K. Theobald, M. Bradshaw, J. Leyden // Skinmed. – 2007. – Vol. 6, № 5. – Р. 221–226.
233.The potential role of microorganisms in the development of rosacea / E. Lazaridou [et al.] // J. Dtsch. Dermatol. Ges. – 2011. –
Vol. 9, № 1. – Р. 21–25.
234.The quality of life impact of acne and rosacea compared to other major medical conditions / N. D. Cresce [et al.] // J. Drugs Dermatol. – 2014.
–Vol. 13, № 6. – Р. 692–697.
235.The role of free oxygen radicals in the aetiopathogenesis of rosacea / M. O. Oztas [et al.] // Clin. Exp. Dermatol. – 2003. – Vol. 28, № 2. – P. 188–192.
236.The seroprevalence of Helicobacter pylori and nitric oxide in acne
rosacea / M. A. Gürer [et al.] // Int. J. Dermatol. – 2002. – Vol. 41,
№11. – P. 768–770.
237.The skin microbiome: Associations between altered microbial communities and disease / L. S. Weyrich [et al.] // Australas. J. Dermatol. – 2015. – Vol. 56, № 4. – Р. 268–274.
238.Tisma, V. S. The role of oxidative stress and iron in pathophysiology of rosacea / V. S. Tisma, M. Poljak-Blazi // Lijec. Vjesn. – 2011. – Vol. 133, № 7/8. – Р. 288–291.
239.Topographical and temporal diversity of the human skin microbiome
/ E. A. Grice [et al.] // Science. – 2009. – Vol. 324 (5931). – P. 1190–1192.
240.Two randomized phase III clinical trials evaluating antiinflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea / J. Q. Del Rosso [et al.] // J. Am. Acad. Dermatol. – 2007. – Vol. 56, № 5. – Р. 791–802.
241.van Zuuren, E. J. Interventions for rosacea: abridged updated Cochrane systematic review including GRADE assessments / E. J. van Zuuren, Z. Fedorowicz // Br. J. Dermatol. – 2015. – Vol. 173, № 3. – Р. 651–662.
242.Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries / D. D. Ku [et al.] // Am. J. Physiol. – 1993. –
Vol. 265, № 2. – Р. 586–592.
243.Ultraviolet B and H2O2 are potent inducers of vascular
endothelial growth |
factor expression |
in cultured keratinocytes |
/ M. Brauchle [et al.] |
// J. Biol. Chem. – |
1996. – Vol. 271, № 36. – |
Р. 21793–21797. |
|
|
|
~ 118 ~ |
|
244.Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis / O. Distler [et al.] // Circ. Res. – 2004. – Vol. 95, № 1. – Р. 109– 116.
245.Uta, S. Treatment of rosacea with ketoconazole / S. Uta, Ü. Ünver
//J. Eur. Acad. Dermatol. Venereol. – 1997. – Vol. 8, № 1. – P. 69–70.
246.UV induces VEGF through a TNF-alpha independent pathway / M. G. Kosmadaki [et al.] // FASEB J. – 2003. – Vol. 17, № 3. – Р. 446–448.
247. Weinkle, A. P. Update on the Management of Rosacea / A. P. Weinkle, V. Doktor, J. Emer // Plast. Surg. Nurs. – 2015. – Vol. 35,
№4. – Р. 184–202.
248.Weinstock, L. B. Rosacea and small intestinal bacterial
overgrowth: prevalence and response to rifaximin / |
L. B. Weinstock, |
M. Steinhoff // J. Am. Acad. Dermatol. – 2013. – |
Vol. 68, № 5. – |
Р. 875–876. |
|
249.Wollina, U. Subantimicrobial-dose doxycycline monohydrate in dermatology / U. Wollina // Wien. Med. Wochenschr. – 2015. – Vol. 165,
№23/24. – Р. 499–503.
250.Yarmolik, A. Rola wskaznikow peroksydacji lipidow I czynnika
wzrostu |
srodblonka naczyniowego w patogenezie tradziku rozowatego |
|
/ A. |
Yarmolik, D. Chworyk // 10-я Академия дерматологии и |
|
аллергологии |
: тез. междунар. науч.-практ. конф., Устка (Польша), |
|
6-9 февр. 2014 |
г. – Устка, 2014. – С. 77. |
~ 119 ~
Научное издание
Хворик Дмитрий Федорович Ярмолик Елена Сергеевна
ПАПУЛО-ПУСТУЛЕЗНАЯ ФОРМА РОЗАЦЕА У ЖЕНЩИН:
этиопатогенез, клиника, диагностика, лечение
Монография
Ответственный за выпуск С. Б. Вольф
Компьютерная верстка С. В. Петрушиной Корректор Л. С. Засельская
Подписано в печать 04.05.2017. Формат 60х84/16. Бумага офсетная. Гарнитура Times New Roman. Ризография.
Усл. печ. л. 6,97. Уч.-изд. л. 5,36. Тираж 50 экз. Заказ 36.
Издатель и полиграфическое исполнение учреждение образования
«Гродненский государственный медицинский университет». ЛП № 02330/445 от 18.12.2013.
Ул. Горького, 80, 230009, г. Гродно.
~ 120 ~